Inventor · disambiguated record
Julien Valton
Also filed as: VALTON JULIEN
20 granted patents·14 pending applications·56 citations·filing 2011–2023
92Inventor score
Top patents by PatentIndex Score
34 records- 0192US10294304B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2016·Granted May 21, 2019·16 cites·22 claims
- 0289US11186824B2Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patientsCELLECTIS·Filed 2016·Granted Nov 30, 2021·4 cites·22 claims
- 0389US10239948B2Method of engineering multi-input signal sensitive T cell for immunotherapyCELLECTIS·Filed 2014·Granted Mar 26, 2019·16 cites·9 claims
- 0487US9315788B2Method for the generation of compact TALE-nucleases and uses thereofDUCHATEAU PHILIPPE·Filed 2012·Granted Apr 19, 2016·12 cites·33 claims
- 0585US11014989B2Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapyCELLECTIS·Filed 2016·Granted May 25, 2021·2 cites·24 claims
- 0685US10301614B2Method to overcome DNA chemical modifications sensitivity of engineered tale DNA binding domainsCELLECTIS SA·Filed 2013·Granted May 28, 2019·4 cites·16 claims
- 0782US11312782B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2019·Granted Apr 26, 2022·1 cites·46 claims
- 0880US12391933B2Targeted gene insertion for improved immune cells therapyCELLECTIS·Filed 2023·Granted Aug 19, 2025·0 cites·15 claims
- 0974US2022010292A1Method for the generation of compact tale-nucleases and uses thereofCELLECTIS·Filed 2021·Application pending·0 cites
- 1074US2024228636A1mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLSCELLECTIS·Filed 2023·Application pending·0 cites
- 1173US11912776B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2022·Granted Feb 27, 2024·0 cites·24 claims
- 1272US11136566B2Tale-protein scaffolds and uses thereofCELLECTIS·Filed 2019·Granted Oct 5, 2021·0 cites·17 claims
- 1367US10526406B2Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fishCELLECTIS·Filed 2015·Granted Jan 7, 2020·1 cites·6 claims
- 1466US11220683B2Method to overcome DNA chemical modifications sensitivity of engineered TALE DNA binding domainsCELLECTIS·Filed 2019·Granted Jan 11, 2022·0 cites·20 claims
- 1566US2025281613A1Enhancing safety of t-cell-mediated immunotherapyCELLECTIS SA·Filed 2023·Application pending·0 cites
- 1663US2025057952A1Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumorsCELLECTIS SA·Filed 2022·Application pending·0 cites
- 1762US11198856B2Method for the generation of compact tale-nucleases and uses thereofCELLECTIS·Filed 2016·Granted Dec 14, 2021·0 cites·22 claims
- 1862US2025288673A1Gene therapy for the treatment of activated pi3kinase delta syndrome type 1 (apds1)CELLECTIS SA·Filed 2023·Application pending·0 cites
- 1960US12209125B2Targeted gene integration of NK inhibitors genes for improved immune cells therapyCELLECTIS·Filed 2018·Granted Jan 28, 2025·0 cites·20 claims
- 2059US11873511B2Targeted gene insertion for improved immune cells therapyCELLECTIS·Filed 2017·Granted Jan 16, 2024·0 cites·19 claims
- 2156US12221478B2Targeted gene integration of CRS inhibitor genes for improved immune cells therapyCELLECTIS·Filed 2018·Granted Feb 11, 2025·0 cites·7 claims
- 2256US2023248825A1T-cells expressing immune cell engagers in allogenic settingsCELLECTIS SA·Filed 2021·Application pending·0 cites
- 2354US10472396B2Modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteinsCELLECTIS·Filed 2015·Granted Nov 12, 2019·0 cites·13 claims
- 2454US2014230083A1Modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteinsCELLECTIS·Filed 2013·Application pending·0 cites
- 2553US10813951B2Method of engineering chemotherapy drug resistant T-cells for immunotherapyCELLECTIS·Filed 2014·Granted Oct 27, 2020·0 cites·17 claims
- 2651US11903968B2Engineered immune cells resistant to tumor microenvironmentCELLECTIS·Filed 2018·Granted Feb 20, 2024·0 cites·9 claims
- 2751US2016355875A1Methods and kits for detecting nucleic acid sequences of interest using dna-binding protein domainCELLECTIS·Filed 2014·Application pending·0 cites
- 2848US10894093B2Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivationCELLECTIS·Filed 2017·Granted Jan 19, 2021·0 cites·21 claims
- 2944US2019328783A1A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expressionCELLECTIS·Filed 2017·Application pending·0 cites
- 3044US2014309145A1High throughput method for assembly and cloning polynucleotides comprising highly similar polynucleotidic modulesVALTON JULIEN·Filed 2012·Application pending·0 cites
- 3143US2019290694A1Stably enginereed proteasome inhibitor resistant immune cells for immunotherapyCELLECTIS·Filed 2017·Application pending·0 cites
- 3239US2017198306A1Engineering mammalian genome using dna-guided argonaute interference systems (dais)CELLECTIS·Filed 2015·Application pending·0 cites
- 3337US2018171298A1Methods for improving functionality in nk cell by gene inactivation using specific endonucleaseCELLECTIS·Filed 2016·Application pending·0 cites
- 3436US2013196320A1Method for improving cleavage of dna by endonuclease sensitive to methylationDUCHATEAU PHILIPPE·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Julien Valton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →